Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25912710 | 0.88 | DPP4 (0.43) | DPP4PREPFAPCYP2D6DPP8 | |
| SCHEMBL23323542 | 0.84 | CHRM2 (0.30) | DPP4PREPFAP | |
| SCHEMBL23342597 | 0.84 | MAPT (0.31) | DPP4CYP2D6DPP8DPP9DPP7 | |
| SCHEMBL26051947 | 0.82 | — | — | |
| SCHEMBL26046365 | 0.82 | — | — | |
| SCHEMBL25909060 | 0.80 | CNR1 (0.31) | DPP4 | |
| SCHEMBL25895277 | 0.76 | DPP4 (0.38) | DPP4PREPFAP | |
| SCHEMBL23323553 | 0.74 | DPP4 (0.35) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL25895288 | 0.72 | DPP4 (0.34) | DPP4PREPFAP | |
| SCHEMBL8293473 | 0.69 | DPP4 (0.41) | DPP4PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | DPP4 3544/4885PREP 2469/4885FAP 304/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | DPP4 3661/4885PREP 3036/4885FAP 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.